Clinical practice guidelines for the management of children with mother-to-child transmitted hepatitis C virus infection.
Minds
clinical practice guidelines
direct acting antivirals
hepatitis C virus infection
mother-to-child transmission
Journal
Pediatrics international : official journal of the Japan Pediatric Society
ISSN: 1442-200X
Titre abrégé: Pediatr Int
Pays: Australia
ID NLM: 100886002
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
12
07
2021
accepted:
10
08
2021
entrez:
28
2
2022
pubmed:
1
3
2022
medline:
3
3
2022
Statut:
ppublish
Résumé
The first guidelines for care of pregnant women carrying the hepatitis C virus (HCV) and their infants were published in 2005 in Japan. Since then, evidence has gradually accumulated worldwide regarding the natural course and treatment of this condition and, especially in recent years, treatment for chronic hepatitis C in adult patients has made great progress. However, the clinical practice policy for children has not been standardized, and new clinical practice guidelines for children with mother-to-child (MTC) transmitted HCV infection have become necessary. In the development of the current guideline, we requested cooperation from The Japanese Society for Pediatric Infectious Diseases, The Japan Society of Hepatology, and the Japan Society of Obstetrics and Gynecology. The committee members were recommended and approved by each society to participate in developing the guidelines. The guideline was also created in accordance with the Minds Guide for Practice Guideline Development. The statements were prepared by consensus-building using the Delphi method, based on the comprehensively searched academic papers and guidelines. These articles were retrieved through searching the PubMed, Cochrane Library, and the Igaku Chuo Zasshi databases. Eight clinical questions (CQs) with clinical statements were developed regarding etiology (CQs 1-3), diagnosis (CQs 4 and 5), and treatment (two CQs 6 and 7). In each statement, the consensus rate, evidence level, and recommendation level were determined. The guidelines will be helpful in the management of children with hepatitis C MTC transmission.
Sections du résumé
BACKGROUND
BACKGROUND
The first guidelines for care of pregnant women carrying the hepatitis C virus (HCV) and their infants were published in 2005 in Japan. Since then, evidence has gradually accumulated worldwide regarding the natural course and treatment of this condition and, especially in recent years, treatment for chronic hepatitis C in adult patients has made great progress. However, the clinical practice policy for children has not been standardized, and new clinical practice guidelines for children with mother-to-child (MTC) transmitted HCV infection have become necessary.
METHODS
METHODS
In the development of the current guideline, we requested cooperation from The Japanese Society for Pediatric Infectious Diseases, The Japan Society of Hepatology, and the Japan Society of Obstetrics and Gynecology. The committee members were recommended and approved by each society to participate in developing the guidelines. The guideline was also created in accordance with the Minds Guide for Practice Guideline Development. The statements were prepared by consensus-building using the Delphi method, based on the comprehensively searched academic papers and guidelines. These articles were retrieved through searching the PubMed, Cochrane Library, and the Igaku Chuo Zasshi databases.
RESULTS
RESULTS
Eight clinical questions (CQs) with clinical statements were developed regarding etiology (CQs 1-3), diagnosis (CQs 4 and 5), and treatment (two CQs 6 and 7). In each statement, the consensus rate, evidence level, and recommendation level were determined.
CONCLUSION
CONCLUSIONS
The guidelines will be helpful in the management of children with hepatitis C MTC transmission.
Types de publication
Journal Article
Practice Guideline
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14962Subventions
Organisme : Japan Agency for Medical Research and Development
ID : 20fk0210068h0001
Informations de copyright
© 2022 Japan Pediatric Society.
Références
Tajiri H, Miyoshi Y, Funada S et al. Prospective study of mother-to-infant transmission of hepatitis C virus. Pediatr. Infect. Dis. J. 2001; 20: 10-4.
Ceci O, Margiotta M, Marello F et al. Vertical transmission of hepatitis C virus in a cohort of 2,447 HIV-seronegative pregnant women: a 24-month prospective study. J. Pediatr. Gastroenterol. Nutr. 2001; 33: 570-5.
Miyoshi Y, Sawada A, Kozaiwa K et al. Prospective study of mother-to-infant transmission of hepatitis C virus. Study of transmission rate and risk factors. J. Jpn. Soc. Pediatr. Gastroenterol. Hepatol. Nutr. 2002; 16: 29. [in Japanese]
Ferrero S, Lungaro P, Bruzzone BM et al. Prospective study of mother-to-infant transmission of hepatitis C virus: a 10-year survey. Acta. Obstet. Gynecol. Scand. 2003; 82: 229-34.
Mast EE, Hwang LY, Seto DS et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J. Infect. Dis. 2005; 192: 1880-9.
Syriopoulou V, Nikolopoulou G, Daikos GL et al. Mother to child transmission of hepatitis C virus: rate of infection and risk factors. Scand. J. Infect. Dis. 2005; 37: 350-3.
Hayashida A, Inaba N, Oshima K et al. Re-evaluation of the true rate of hepatitis C virus mother-to-child transmission and its novel risk factors based on our two prospective studies. J. Obstet. Gynaecol. Res. 2007; 33: 417-22.
Hayashida A, Inaba N, Oshima K et al. Re-evaluation of clinical significance of HCV mother-to-child transmission (MTCT) based on our own two prospective studies divided by periods, and the new risk factors for HCV MTCT. J. Jpn. Soc. Obstet. Gynecol. 2007; 59: 780.
Marine-Barjoan E, Berrebi A, Giordanengo V et al. HCV/HIV co-infection, HCV viral load and mode of delivery: risk factors for mother-to-child transmission of hepatitis C virus? AIDS 2007; 21: 1811-5.
Ngo-Giang-Huong N, Jourdain G, Sirirungsi W et al. Human immunodeficiency virus-hepatitis C virus co-infection in pregnant women and perinatal transmission to infants in Thailand. Int. J. Infect. Dis. 2010; 14: e602-7.
Murakami J, Iizuka T, Nagata I et al. Study of temporal transition of the number of HCV-positive pregnant women and risk factors for mother-to-child transmission. J. Jpn. Pediatr. Soc. 2010; 114: 247. [in Japanese].
Ruiz-Extremera A, Muñoz-Gámez JA, Salmerón-Ruiz MA et al. Genetic variation in interleukin 28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV-infected children. Hepatology 2011; 53: 1830-8.
Delotte J, Barjoan EM, Berrébi A et al. Obstetric management does not influence vertical transmission of HCV infection: results of the ALHICE group study. J. Matern. Fetal. Neonatal. Med. 2014; 27: 664-70.
Elrazek AE, Amer M, Hawary B et al. Prediction of HCV vertical transmission: what are factors should be optimized using data mining computational analysis. Liver Int. 2017; 37: 529-33.
Granovsky MO, Minkoff HL, Tess BH et al. Hepatitis C virus infection in the mothers and infants cohort study. Pediatrics 1998; 102: 355-9.
Garland SM, Tabrizi S, Robinson P et al. Hepatitis C-role of perinatal transmission. Aust. N Z J. Obstet. Gynaecol. 1998; 38: 424-7.
Dal Molin G, D'Agaro P, Ansaldi F et al. Mother-to-infant transmission of hepatitis C virus: rate of infection and assessment of viral load and IgM anti-HCV as risk factors. J. Med. Virol. 2002; 67: 137-42.
Paternoster DM, Belligoli A, Ngaradoumbe NK et al. Endogenous interferon-alpha level is increased in hepatitis C virus (HCV)-positive pregnant women. J. Clin. Gastroenterol. 2008; 50: 204-7.
Murakami J, Nagata I, Iitsuka T et al. Risk factors for mother-to-child transmission of hepatitis C virus: maternal high viral load and fetal exposure in the birth canal. Hepatol. Res. 2012; 42: 648-57.
Garcia-Tejedor A, Maiques-Montesinos V, Diago-Almela VJ et al. Risk factors for vertical transmission of hepatitis C virus: a single center experience with 710 HCV-infected mothers. Eur. J. Obstet. Gynecol. Reprod. Biol. 2015; 194: 173-7.
Xiong SK, Okajima Y, Ishikawa K et al. Vertical transmission of hepatitis C virus: risk factors and infantile prognosis. J. Obstet. Gynaecol. Res. 1998; 24: 57-61.
Papaevangelou V, Pollack H, Rochford G et al. Increased transmission of vertical hepatitis C virus (HCV) infection to human immunodeficiency virus (HIV)-infected infants of HIV- and HCV-coinfected women. J. Infect. Dis. 1998; 178: 1047-52.
Mazza C, Ravaggi A, Rodella A et al. Prospective study of mother-to-infant transmission of hepatitis C virus (HCV) infection. Study group for vertical transmission. J. Med. Virol. 1998; 54: 12-9.
Xiong S, Ishikawa K, Tanaka S et al. Hepatitis C virus; risk factors for mother-to-child transmission and the possibility of marital infection. Proc. Jpn. Soc. Infect. Dis. Obstet. Gynecol. 1998; 15: 47-8. [in Japanese].
Inaba N, Ohshima K, Nishikawa M et al. Hepatitis C virus. HCV in mother-to-child transmission. Obstet. Gynecol. Pract. 2003; 52: 901-6. [in Japanese]
Ikeda A, Nishikawa M, Okazaki T et al. Risk factors for HCV mother-to-child transmission in comparison with HGV mother-to-child transmission. Proc. Jpn. Soc. Infect. Dis. Obstet. Gynecol. 2004; 22: 49-54. [in Japanese].
Saez A, Losa M, Lo Iacono O et al. Diagnostic and prognostic value of virologic tests in vertical transmission of hepatitis C virus infection: results of a large prospective study in pregnant women. Hepatogastroenterology 2004; 51: 1104-8.
Steininger C, Kundi M, Jatzko G et al. Increased risk of mother-to-infant transmission of hepatitis C virus by intrapartum infantile exposure to maternal blood. J. Infect. Dis. 2003; 187: 345-51.
Kowala-Piaskowska A, Figlerowicz M, Mozer-Lisewska I et al. Prediction of HCV vertical transmission: what are factors should be optimized using data mining computational analysis. Hepatol. Res. 2004; 30: 137-40.
Shiraki K, Ohto H, Inaba N et al. Guidelines for care of pregnant women carrying hepatitis C virus and their infants. Pediatr. Int. 2008; 50: 138-40.
Bonacini M, Puoti M. Hepatitis C in patients with human immunodeficiency virus infection: diagnosis, natural history, meta-analysis of sexual and vertical transmission, and therapeutic issues. Arch. Intern. Med. 2000; 160: 3365-73.
Hadzic N. Hepatitis C in pregnancy. Arch. Dis. Child Fetal Neonatal Ed. 2001; 84: F201-4.
Valladares G, Chacaltana A, Sjogren MH. The management of HCV-infected pregnant women. Ann. Hepatol. 2010; 9: S92-7.
Murakami J, Nagata I. Hepatitis C virus. HCV infection and prevention measures. Prevention measures of mother-to-child transmission and household infection. Nippon Rinsho 2011; 69: 122-7. [in Japanese]
Floreani A. Hepatitis C and pregnancy. World J. Gastroenterol. 2013; 19: 6714-20.
Resti M. Mother-to-infant transmission of hepatitis C virus. Ital. J. Gastroenterol. Hepatol. 1999; 31: 489-93.
Conte D, Colucci A, Minola E et al. Clinical course of pregnant women with chronic hepatitis C virus infection and risk of mother-to-child hepatitis C virus transmission. Dig. Liver. Dis. 2001; 33: 366-71.
Airoldi J, Berghella V. Hepatitis C and pregnancy. Obstet. Gynecol. Surv. 2006; 61: 666-72.
Le Campion A, Larouche A, Fauteux-Daniel S et al. Pathogenesis of hepatitis C during pregnancy and childhood. Viruses 2012; 4: 3531-50.
Resti M, Bortolotti F, Vajro P et al. Guidelines for the screening and follow-up of infants born to anti-HCV positive mothers. Dig. Liver Dis. 2003; 35: 453-7.
Baker RD, Baker SS. Hepatitis C in children in times of change. Curr. Opin. Pediatr. 2015; 27: 614-8.
American Academy of Pediatrics: Hepatitis C. Red Book: 2018 Report of the Committee on Infectious Diseases, 31st ed. Itasca, IL, American Academy of Pediatrics; 2018; 428-34.
Ghamar Chehreh ME, Tabatabaei SV, Khazanehdari S, Alavian SM. Effect of cesarean section on the risk of perinatal transmission of hepatitis C virus from HCV-RNA+/HI- mothers: a meta-analysis. Arch. Gynecol. Obstet. 2011; 283: 255-60.
McIntyre PG, Tosh K, McGuire W. Caesarean section versus vaginal delivery for preventing mother to infant hepatitis C virus transmission. Cochrane Database Syst. Rev. 2006; 4: CD005546.
Cottrell EB, Chou R, Wasson N, Rahman B, Guise JM. Reducing risk for mother-to-infant transmission of hepatitis C virus: a systematic review for the U.S. preventive services task force. Ann. Intern. Med. 2013; 158: 109-13.
Kinugasa M, Tamai H, Bian S, Shimizu T, Kanzaki T. Is Caesarean section effective in preventing hepatitis C virus mother-to-child transmission? J. Jpn. Soc. Perinat. Neonat. Med. 2013; 49: 925-30.
Murakami J, Nagata I, Iitsuka T et al. Risk factors for mother-to-child transmission of hepatitis C virus: maternal high viral load and fetal exposure in the birth canal. Hepatol. Res. 2012; 42: 648-57.
CQ607 What if HCV antibody positive is found during pregnancy? Obstetrics and Gynecology Practice Guidelines Obstetrics 2020. Page 311-12.
European Pediatric Hepatitis C Virus Network. A significant sex-but not elective cesarean section-effect on mother-to-child transmission of hepatitis C virus infection. J. Infect. Dis. 2005; 192: 1872-9.
European Pediatric Hepatitis C Virus Network. Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus. BJOG 2001; 108: 371-7.
Gibb DM, Goodall RL, Dunn DT et al. Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission. Lancet 2000; 356: 904-7.
Tovo PA, Palomba E, Ferraris G et al. Increased risk of maternal-infant hepatitis C virus transmission for women coinfected with human immunodeficiency virus type 1. Italian Study Group for HCV Infection in Children. Clin. Infect. Dis. 1997; 25: 1121-4.
Zanetti AR, Tanzi E, Romano L et al. A prospective study on mother-to-infant transmission of hepatitis C virus. Intervirology 1998; 41: 208-12.
Resti M, Azzari C, Mannelli F et al. Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. Tuscany study group on hepatitis C virus infection. BMJ 1998; 317: 437-41.
Pipan C, Amici S, Astori G et al. Vertical transmission of hepatitis C virus in low-risk pregnant women. Eur. J. Clin. Microbiol. Infect. Dis. 1996; 15: 116-20.
Lin HH, Kao JH, Hsu HY et al. Absence of infection in breast-fed infants born to hepatitis C virus-infected mothers. J. Pediatr. 1995; 126: 589-91.
Polywka S, Schroter M, Feucht HH et al. Low risk of vertical transmission of hepatitis C virus by breast milk. Clin. Infect. Dis. 1999; 29: 1327-9.
Resti M, Azzari C, Galli L et al. Maternal drug use is a preeminent risk factor for mother-to-child hepatitis C virus transmission: results from a multicenter study of 1372 mother-infant pairs. J. Infect. Dis. 2002; 185: 567-72.
Kumar RM, Shahul S. Role of breast-feeding in transmission of hepatitis C virus to infants of HCV-infected mothers. J. Hepatol. 1998; 29: 191-7.
Cottrell EB, Chou R, Wasson N et al. Reducing risk for mother-to-infant transmission of hepatitis C virus: a systematic review for the U.S. preventive services task force. Ann. Intern. Med. 2013; 158: 109-13.
Bhola K, McGuire W. Does avoidance of breast feeding reduce mother-to-infant transmission of hepatitis C virus infection? Arch. Dis. Child. 2007; 92: 365-6.
Yeung LT, King SM, Roberts EA. Mother-to-infant transmission of hepatitis C virus. Hepatology 2001; 34: 223-9.
Ujiie N, Yamagiwa K, Suzuki H et al. Examination of the significance of breastfeeding in HCV mother-to-child transmission. Fukushima Med. J. 1998; 48: 54-5.
Polywka S, Feucht H, Zollner B et al. Hepatitis C virus infection in pregnancy and the risk of mother-to-child transmission. Eur. J. Clin. Microbiol. Infect. Dis. 1997; 16: 121-4.
Spencer JD, Latt N, Beeby PJ et al. Transmission of hepatitis C virus to infants of human immunodeficiency virus-negative intravenous drug-using mothers: rate of infection and assessment of risk factors for transmission. J. Viral. Hepat. 1997; 4: 395-409.
Gillett P, Hallam N, Mok J. Vertical transmission of hepatitis C virus infection. Scand. J. Infect. Dis. 1996; 28: 549-52.
Resti M, Bortolotti F, Vajro P, Maggiore G. Guidelines for the screening and follow-up of infants born to anti-HCV positive mothers. Dig. Liver. Dis. 2003; 35: 453-7.
Shiraki K, Ohto H, Inaba N et al. Guidelines for care of pregnant women carrying hepatitis C virus and their infants. Pediatr. Int. 2008; 50: 138-40.
[Cited 24 December 2019.] Available from http://www.kanen.ncgm.go.jp/cont/010/c_gata.html
Wen JW, Haber BA. Maternal-fetal transmission of hepatitis C infection: what is so special about babies? J. Pediatr. Gastroenterol. Nutr. 2014; 58: 278-82.
Arshad M, El-Kamary SS, Jhaveri R. Hepatitis C virus infection during pregnancy and the newborn period-are they opportunities for treatment? J. Viral. Hepat. 2011; 18: 229-36.
Lam NC, Gotsch PB, Langan RC. Caring for pregnant women and newborns with hepatitis B or C. Am. Fam. Physician 2010; 82: 1225-9.
Powell M, Bailey J, Maggio LA. Clinical inquiries. How should you manage children born to hepatitis C-positive women? J. Fam. Pract. 2010; 59: 289-90.
Davison SM, Mieli-Vergani G, Sira J, Kelly DA. Perinatal hepatitis C virus infection: diagnosis and management. Arch. Dis. Child. 2006; 91: 781-5.
Indolfi G, Resti M. Perinatal transmission of hepatitis C virus infection. J. Med. Virol. 2009; 81: 836-43.
Roberts EA, Yeung L. Maternal-infant transmission of hepatitis C virus infection. Hepatology 2002; 36: S106-13.
Thomas SL, Newell ML, Peckham CS, Ades AE, Hall AJ. Use of polymerase chain reaction and antibody tests in the diagnosis of vertically transmitted hepatitis C virus infection. Eur. J. Clin. Microbiol. Infect. Dis. 1997; 16: 711-9.
Polywka S, Pembrey L, Tovo PA, Newell ML. Accuracy of HCV-RNA PCR tests for diagnosis or exclusion of vertically acquired HCV infection. J. Med. Virol. 2006; 78: 305-10.
European Paediatric Hepatitis C Virus Network. Three broad modalities in the natural history of vertically acquired hepatitis C virus infection. Clin. Infect. Dis. 2005; 41: 45-51.
Sasaki N, Matsui A, Momoi M, Tsuda F, Okamoto H. Loss of circulating hepatitis C virus in children who developed a persistent carrier state after mother-to-baby transmission. Pediatr. Res. 1997; 42: 263-7.
Ferrero S, Lungaro P, Bruzzone BM, Gotta C, Bentivoglio G, Ragni N. Prospective study of mother-to-infant transmission of hepatitis C virus: a 10-year survey (1990-2000). Acta. Obstet. Gynecol. Scand. 2003; 82: 229-34.
Healy CM, Cafferkey MT, Conroy A et al. Outcome of infants born to hepatitis C infected women. Ir. J. Med. Sci. 2001; 170: 103-6.
Conte D, Fraquelli M, Prati D, Colucci A, Minola E. Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women. Hepatology 2000; 31: 751-5.
Shebl FM, El-Kamary SS, Saleh DA et al. Prospective cohort study of mother-to-infant infection and clearance of hepatitis C in rural Egyptian villages. J. Med. Virol. 2009; 81: 1024-31.
Resti M, Azzari C, Mannelli F et al. Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. Tuscany study group on hepatitis C virus infection. BMJ 1998; 317: 437-41.
Ujiie J, Yamagiwa K, Suzuki H et al. Study on mother-to-child HCV transmission (1st report). Acta. Neonatologica. Japonica 1993; 29: 507-12.
Tovo PA, Lazier L. Versace: hepatitis B virus and hepatitis C virus infections in children. Curr. Opin. Infect. Dis. 2005; 18: 261-6.
Arshad M, El-Kamary SS, Jhaveri R. Hepatitis C virus infection during pregnancy and the newborn period-are they opportunities for treatment? J. Viral. Hepat. 2011; 18: 229-36.
Serranti D, Buonsenso D, Ceccarelli M et al. Pediatric hepatitis C infection: to treat or not to treat..what's the best for the child? Eur. Rev. Med. Pharmacol. Sci. 2011; 15: 1057-67.
Zuccotti GV, Torcoletti M, Salvini F et al. Infants vertically infected with hepatitis C: a long-term longitudinal follow-up. Pediatr. Med. Chir. 2004; 26: 50-2.
Yeung LT, To T, King SM, Roberts EA. Spontaneous clearance of childhood hepatitis C virus infection. J. Viral. Hepat. 2007; 14: 797-805.
Ruiz-Extremera A, Munoz-Gamez JA, Salmeron-Ruiz MA et al. Genetic variation in interleukin 28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV-infected children. Hepatology 2011; 53: 1830-8.
Farmand S, Wirth S, Loffler H et al. Spontaneous clearance of hepatitis C virus in vertically infected children. Eur. J. Pediatr. 2012; 171: 253-8.
Garazzino S, Calitri C, Versace A et al. Natural history of vertically acquired HCV infection and associated autoimmune phenomena. Eur. J. Pediatr. 2014; 173: 1025-31.
Resti M, Jara P, Hierro L et al. Clinical features and progression of perinatally acquired hepatitis C virus infection. J. Med. Virol. 2003; 70: 373-7.
Tovo PA, Pembrey LJ, Newell ML. Persistence rate and progression of vertically acquired hepatitis C infection. European paediatric hepatitis C virus infection. J. Infect. Dis. 2000; 181: 419-24.
Simanis R, Lejniece S, Sochnevs A et al. Natural clearance of hepatitis C virus in hemophilia patients. Medicina (Kaunas) 2008; 44: 15-21.
Goncales FL Jr, Stucchi RS, Pavan MH, Angerami RN, Goncales NS. Hepatitis C virus in monozygotic twins. Rev. Inst. Med. Trop. Sao Paulo 2000; 42: 163-5.
Miyoshi Y, Etani Y, Mushiake S, Ozono K. Natural course of the infants transmitted hepatitis C virus from the mothers. Nihon Rinsho 2004; 62 (suppl 7): 279-82. [in Japanese].
Abdel-Hady M, Bunn SK, Sira J et al. Chronic hepatitis C in children-review of natural history at a national centre. J. Viral. Hepat. 2011; 18: e535-40.
Mohan N, Gonzalez-Peralta RP, Fujisawa T et al. Chronic hepatitis C virus infection in children. J. Pediatr. Gastroenterol. Nutr. 2010; 50: 123-31.
Jonas MM. Challenges in the treatment of hepatitis C in children. Clin. Liver. Dis. 2001; 5: 1063-71.
Miyoshi Y, Tajiri H. Hepatitis virus C infection in children. Nihon Rinsho 2001; 59: 1294-8.
Schwimmer JB, Balistreri WF. Transmission, natural history, and treatment of hepatitis C virus infection in the pediatric population. Semin. Liver. Dis. 2000; 20: 37-46.
Ikeda A, Nishikawa M, Okazaki T et al. A study of the risk factor of the HCV-vertically transmission in comparison with the HGV-vertically transmission. Jpn. Obstet. Gynecol. Infect. Dis. Study Group Acad. Lect. Rec. Collect. 2004; 22: 49-54.[in Japanese]
Terazawa S, Kato Z, Hukutomi T, Kondo N. Investigation on clinical backgrounds of HCV-infected infants found out by prospective studies for materno-fetal transmission of HCV. JSPGHAN 1998; 12: 143-8. [in Japanese].
Sogo T, Inui A, Morinishi Y et al. Clinical courses of mother-to-infant transmission of hepatitis C virus. J. Pediatr. Infect. Dis. Immun. 1998; 10: 303-8. [in Japanese].
Kashiwa H, Kubo N, Arashin O. Mother-to-infant transmission of hepatitis C virus. Hiroshma. Med. 1995; 48: 893-6. [in Japanese].
Inaba N, Shimizu K, Shimizu B, Takamizawa H. A prospective follow-up study demonstrating the vertical transmission of hepatitis C virus. Chiba Med. J. 1993; 69: 67-72. [in Japanese].
Rerksuppaphol S, Hardikar W, Dore GJ. Long-term outcome of vertically acquired and post-transfusion hepatitis C infection in children. J. Gastroenterol. Hepatol. 2004; 19: 1357-62.
England K, Thorne C, Harris H, Ramsay M, Newell ML. The impact of mode of acquisition on biological markers of paediatric hepatitis C virus infection. J. Viral. Hepat. 2011; 18: 533-41.
Palomba E, Manzini P, Fiammengo P, Maderni P, Saracco G, Tovo PA. Natural history of perinatal hepatitis C virus infection. Clin. Infect. Dis. 1996; 23: 47-50.
Miyoshi Y. Study of the natural course of infants-transmitted with hepatitis C virus from the mothers. Med. J. Osaka Univ. 2000; 52: 189-94. [in Japanese].
Mack CL, Gonzalez-Peralta RP, Gupta N et al. North American society for pediatric gastroenterology, hepatology, and nutrition. NASPGHAN practice guidelines: diagnosis and management of hepatitis C infection in infants, children, and adolescents. J. Pediatr. Gastroenterol. Nutr. 2012; 54: 838-5.
Chang MH. Mother-to-infant transmission of hepatitis C virus. Clin. Invest. Med. 1996; 19: 368-72.
Tajiri H, Tanaka Y, Takano T et al. Association of IL28B polymorphisms with virological response to peginterferon and ribavirin therapy in children and adolescents with chronic hepatitis C. Hepatol. Res. 2014; 44: E38-44.
Hartwell D, Cooper K, Frampton GK et al. The clinical effectiveness and cost-effectiveness of peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people: a systematic review and economic evaluation. Health Technol. Assess. 2014; 18: i-xxii.
Druyts E, Thorlund K, Wu P et al. Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis. Clin. Infect. Dis. 2013; 56: 961-7.
Indolfi G, Guido M, Azzari C et al. Histopathology of hepatitis C in children, a systematic review: implications for treatment. Expert Rev. Anti. Infect. Ther. 2015; 13: 1225-35.
Schwarz KB, Gonzalez-Peralta RP, Murray KF et al. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology 2011; 140: 450-8.
Balistreri WF, Murray KF, Rosenthal P et al. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection. Hepatology 2017; 66: 371-8.
Wirth S, Rosenthal P, Gonzalez-Peralta RP et al. Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infection. Hepatology 2017; 66: 1102-10.
Jonas MM, Squires RH, Rhee SM et al. Pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir in adolescents with chronic hepatitis C virus: part 1 of the DORA study. Hepatology 2019; 71: 456-62.
Suzuki M, Tajiri H, Tanaka Y et al. Peginterferon therapy in children with chronic hepatitis C: a nationwide, multicenter study in Japan, 2004-2013. J. Pediatr. Gastroenterol. Nutr. 2016; 63: 88-93.
Tajiri H, Inui A, Kiyohara Y et al. Peginterferon alpha-2b and ribavirin for the treatment of chronic hepatitis C in Japanese pediatric and young adult patients: a survey of the Japan society of pediatric hepatology. Eur. J. Gastroenterol. Hepatol. 2009; 21: 1256-60.
Komatsu H, Inui A, Tsunoda T et al. Association between an IL-28B genetic polymorphism and the efficacy of the response-guided pegylated interferon therapy in children with chronic hepatic C infection. Hepatol. Res. 2013; 43: 327-38.
Sokal EM, Bourgois A, Stéphenne X et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents. J. Hepatol. 2010; 52: 827-31.
Wirth S, Pieper-Boustani H, Lang T et al. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology 2005; 41: 1013-8.
Wiśniewska-Ligier M, Pawłowska M, Pilarczyk M et al. Efficacy of pegylated interferon α-2b and ribavirin in chronic hepatitis C virus (genotypes 1 and 4) infection. J. Pediatr. Gastroenterol. Nutr. 2013; 57: 694-9.
Rosen I, Kori M, Eshach Adiv O. Pegylated interferon alfa and ribavirin for children with chronic hepatitis C. World J. Gastroenterol. 2013; 19: 1098-103.
Aziz S, Rajper J, Noorulain W. Treatment outcome of HCV infected paediatric patients and young adults at Karachi, Pakistan. J. Ayub Med. Coll. Abbottabad 2012; 24: 56-8.
Słuzewski W, Kowala-Piaskowska A, Wysocki J et al. Treatment of chronic hepatitis C in children with pegylated interferon α2a and ribavirin-a multi-center study. Acta Pol. Pharm. 2012; 69: 319-26.
Baker RD, Dee D, Baker SS. Response to pegylated interferon alpha-2b and ribavirin in children with chronic hepatitis C. J. Clin. Gastroenterol. 2007; 41: 111-4.
Schwarz KB, Molleston JP, Jonas MM et al. Durability of response in children treated with pegylated interferon alfa [corrected] 2a ± ribavirin for chronic hepatitis C. J. Pediatr. Gastroenterol. Nutr. 2016; 62: 93-6.
Tsunoda T, Inui A, Kawamoto M et al. Effects of pegylated interferon-α-2a monotherapy on growth in Japanese children with chronic hepatitis C. Hepatol. Res. 2014; 44: 251-8.
Wirth S, Ribes-Koninckx C, Calzado MA et al. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J. Hepatol. 2010; 52: 501-7.
Jara P, Hierro L, de la Vega A et al. Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection. Pediatr. Infect. Dis. J. 2008; 27: 142-8.
Gonzalez-Peralta RP, Kelly DA, Haber B et al. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. Hepatology 2005; 42: 1010-8.
Jonas MM, Schwarz KB, Gonzalez-Peralta R et al. Long-term growth outcomes in children treated for chronic hepatitis C. J. Pediatr. 2014; 165: 1252-4.
Abdel-Hady M, Bansal S, Davison SM et al. Treatment of chronic viral hepatitis C in children and adolescents: UK experience. Arch. Dis. Child. 2014; 99: 505-10.
Haber B, Alonso E, Pedreira A et al. Long-term follow-up of children treated with peginterferon and ribavirin for hepatitis C virus infection. J. Pediatr. Gastroenterol. Nutr. 2017; 64: 89-94.
Mohan P, Barton BA, Narkewicz MR et al. Evaluating progression of liver disease from repeat liver biopsies in children with chronic hepatitis C: a retrospective study. Hepatology 2013; 58: 1580-6.
Goodman ZD, Makhlouf HR, Liu L et al. Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial. Hepatology 2008; 47: 836-43.
Bortolotti F, Verucchi G, Cammà C et al. Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease. Gastroenterology 2008; 134: 1900-7.
Kage M, Fujisawa T, Shiraki K et al. Pathology of chronic hepatitis C in children. Child liver study group of Japan. Hepatology 1997; 26: 771-5.
Mizuochi T, Takano T, Yanagi T et al. Epidemiologic features of 348 children with hepatitis C virus infection over a 30-year period: a nationwide survey in Japan. J. Gastroenterology 2017; 53: 419-26.
González-Peralta RP, Langham MR Jr, Andres JM et al. Hepatocellular carcinoma in 2 young adolescents with chronic hepatitis C. J Pediatr. Gastroenterol. Nutr. 2009; 48: 630-5.
El Shervini A, Mostafa S, Alli E. Systematic review with meta-analysis: comparison between therapeutic regimens for paediatric chronic hepatitis C. Aliment. Pharmacol. Ther. 2015; 42: 12-9.
Jonas MM, Balistreri W, Gonzalez-Peralta RP et al. Pegylated interferon for chronic hepatitis C in children affects growth and body composition: results from the pediatric study of hepatitis C (PEDS-C) trial. Hepatology 2012; 56: 523-31.
Strickland DK, Jenkins JJ, Hudson MM. Hepatitis C infection and hepatocellular carcinoma after treatment of childhood cancer. J. Pediatr. Hematol. Oncol. 2001; 23: 527-9.
Azuhata T, Koshinaga T, Tanaka M et al. Hepatocellular carcinoma complicating biliary atresia caused by HCV infection: a case report. J. Jap. Soc. Pediatr. Surg. 2003; 39: 765-70.